Get startedLog in
    Picture of Carisma Therapeutics logo

    CARM — Carisma Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapValue Trap
    All News

    Brief: Sesen Bio Reports Fourth Quarter And Full-Year 2022 Financial Results

    Picture of Carisma Therapeutics logoCarisma Therapeutics
    28/02/2023 14:48
    Feb 28 (Reuters) - Sesen Bio Inc  SESN.O :
    * SESEN BIO REPORTS FOURTH QUARTER AND FULL-YEAR 2022
FINANCIAL
RESULTS
    * SESEN BIO INC Q4 LOSS PER SHARE $0.04
    * BOARD BELIEVES PENDING MERGER WITH CARISMA IS "MOST
VALUE-MAXIMIZING OPTION FOR STOCKHOLDERS"
    * BOARD UNANIMOUSLY RECOMMENDS ALL STOCKHOLDERS VOTE "FOR"
CARISMA
MERGER TRANSACTION AHEAD OF MARCH 2, 2023 SPECIAL MEETING OF
STOCKHOLDERS

Source text for Eikon:  ID:nBw2kYWZJa 
Further company coverage:  SESN.O

    Recent news on Carisma Therapeutics

    See all news